Physician profile
Jill Captain
NPI 1942469390
$1,050.53
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $33.65 · 2020: $318 · 2021: $575 · 2023: $124.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $124.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $123.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $144.42 | 2020-2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $123.50 | 2023 | |
| Lilly USA, LLC | $121.96 | 2020-2021 | |
| Astrazeneca Pharmaceuticals LP | $108.83 | 2019-2021 | |
| Daiichi Sankyo INC. | $97.43 | 2020-2021 | |
| Gilead Sciences, INC. | $80.62 | 2020-2021 | |
| Allergan, INC. | $55.56 | 2020 | |
| Adlon Therapeutics L.P. | $41.70 | 2020-2021 | |
| Novo Nordisk INC | $41.45 | 2020-2021 | |
| Glaxosmithkline, LLC. | $40.77 | 2020-2021 | |
| Neos Therapeutics, LP | $35.74 | 2021 | |
| Amgen INC. | $35.73 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $33.88 | 2020-2021 | |
| Genentech, INC. | $20.92 | 2019 | |
| Pfizer INC. | $15.75 | 2021 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $14.43 | 2020 | |
| Eisai INC. | $13.24 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $12.85 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $11.75 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jill Captain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.